This paper reviews the available data on the prevalence of thrombophilia defects in patients with peripheral vascular disease (PVD) and attempts to delineate the risk of failure of vascular intervention in these patients. The prevalence of thrombophilia in stable claudicants is 25% and increases to 40% in those requiring revascularisation, compared to only 11% in the control group. The overall prevalence of thrombophilia defects in patients with premature atherosclerosis appears to be between 15 and 30%. The prevalence in the typical cohort of patients with PVD appears to be similar. All these studies have recruited patients with symptoms significant enough to warrant intervention. The overall prevalence of thrombophilia calculated from these trials, therefore, may not be truly indicative of the general vascular population who may not even present primary or secondary healthcare. The risk of thrombotic occlusion following arterial revascularisation in patients with an identified thrombophilia defect appears to be almost three times that of patients with no evidence of a thrombophilia defect. The best management of these patients has not been determined and needs to be evaluated by prospective randomized trials.
Introduction
There are few studies recording the prevalence of thrombophilia defects in patients with vascular disease, which makes it difficult to calculate the overall prevalence of thrombophilia defects in these patients. In addition, the variety of tests used to determine thrombophilia defects makes comparison of different series difficult. This paper reviews the available data on the prevalence of thrombophilia defects in patients with peripheral vascular disease (PVD) and attempts to delineate the risk of failure of vascular intervention in these patients. Individual thrombophilia defects are not discussed in detail as they have recently been reviewed by Burns et al. 1 -5 (Table 1) . It does not include a review of the risk of homocysteine in patients with PVD as this was also covered in detail by the review by O'Grady et al. 6 
Methods
A Medline search was undertaken for English language articles on thrombophilia, hypercoagulability and vascular disease. The same search was also undertaken for arterial and peripheral arterial occlusive disease. In addition each individual thrombophilia defect was also searched using the same strategy. Cross-referencing from the reference lists of relevant major articles identified further papers included in this review.
Prevalence of Thrombophilia Defects in Vascular Patients
There is a higher prevalence of thrombophilia defects in patients with vascular disease compared to the general population. The prevalence of thrombophilia in stable claudicants is 25% and increases to 40% in those requiring revascularisation, compared to only 11% in the control group.
Young patients
There have only been four studies detailing patients with symptoms of lower limb arterial disease who presented at a young age (age , 50) ( Table 2 ). The overall prevalence of thrombophilia defects in patients with premature atherosclerosis appears to be between 15 and 30%. 8 -11 Valentine et al. showed that the prevalence of thrombophilia defects was 15%, twice that of age matched controls. 8 Levy et al.'s study used a comprehensive thrombophilia screen but data are not available to calculate how many patients had multiple defects and, therefore, the overall percentage of these defects. 11 Eldrup-Jorgensen et al.'s study used a limited thrombophilia screen (Antiphospholipid syndrome, Protein C and S deficiencies) and reported a prevalence twice that of Valentine et al.'s study but the same as Aronsen et al. at 30%. 9, 10 Aronsen et al.'s study again only used a limited thrombophilia screen (Protein S, C and Antithrombin deficiencies as well as assays for Von Willebrand factor and Factor VIII). 10 The true prevalence cannot be calculated, as there is difficulty in obtaining a comprehensive screening test for thrombophilia, however, the data summarised in Table 2 suggests an overall prevalence of 30%, but this may well be higher.
Elderly patients
The prevalence of thrombophilia in vascular surgical practice, i.e. elderly patients with PVD is also difficult to elicit. Studies reporting thrombophilia defects in patients with generalised vascular disease are summarised in Table 3 .
Flinn et al. tested for Antithrombin deficiency in patients undergoing procedures varying from aortic aneurysm repair, carotid endarterectomy to femorodistal bypasses and reported a prevalence of 16.2%. 12 Donaldson et al.'s study used a more comprehensive thrombophilia screen (Antithrombin, Protein C and S and lupus anticoagulant) and reported a prevalence of 9.5%. Again the patient group was heterogeneous and included patients with aneurysmal, renovascular, cerebrovascular, aorto-iliac and PVD. 13 Eason et al.'s study retrospectively identified 12 patients with a hypercoagulable state in a four-year period but did not comment on how many were tested overall and therefore the prevalence cannot be calculated. 14 Taylor et al. studied a heterogeneous vascular group and reported a prevalence of 27% with the most common abnormality detected being Antiphospholipid syndrome (26%) (Anticardiolipin and lupus anticoagulant). This study does not comment on the incidence of thrombophilia in the different cohorts. 15 Ouriel et al.'s study only tested for activated Protein C resistance (carotid disease, aortic aneurysms, venous thrombotic disease and lower extremity PVD) and reported a prevalence of 11.6%. 16 Sampram et al.'s study again only tested for a single thrombophilia defect (Factor V mutation) and reported a prevalence of 16%. 17 Only three studies have looked at a typical cohort of patients with PVD. Ray et al. recruited patients attending a vascular clinic with symptoms consistent with lower limb arterial disease. 7 This study reported a prevalence of thrombophilia of 35% based on a comprehensive thrombophilia screen but without testing for Activated Protein C resistance. Lee et al. reported a 32% prevalence of the Antiphospholipid syndrome. 18 The Edinburgh study recruited 116 patients with intermittent claudication with a median age of 65 and reported a prevalence of 21%. 19 All these studies used a variety of criteria to determine thrombophilia. The true prevalence of thrombophilia is difficult to determine based on these limited data. It is more than likely that 25-35% of patients admitted with vascular disease have thrombophilia defects that are unrecognised. If hypercoagulability encompasses patients with known defects and other so far undetermined causes then the overall prevalence maybe much higher.
The most common thrombophilia defect tested was the Antiphospholipid syndrome that may be present in over quarter of the vascular population. Other thrombophilia defects detected in decreasing order of frequency were:
Data relating to prevalence of thrombophilia determined by the type of vascular disease are limited. Ouriel demonstrated that the frequency of APC resistance was highest in a group with lower extremity vascular disease (14%) compared to patients with abdominal aortic aneurysms (12%) and 9% in patients with venous thrombosis. 16 Patients with carotid artery disease had the lowest frequency at 5% (Table 4) . Sampram also showed an increase in prevalence of Factor V Leiden in patients presenting with carotid disease (9%), aneurysmal disease (14%) and PVD (16%). 17 It has been assumed that a thrombophilia defect would affect the whole vascular tree presumably to the same degree. However, it is possible that thrombophilia defects are more prevalent in aggressive disease or lead to severe disease. Lam et al. prospectively monitored progression of lower limb occlusive disease following revascularisation. 20 Patients with evidence of the Antiphospholipid syndrome showed no difference in progression of disease in proximal external iliac or common femoral arteries. However, there was significantly increased progression in superficial femoral and more distal vessels. Multivariate analysis also confirmed a significant independent association between APS and progression of disease.
All these studies have recruited patients with symptoms significant enough to warrant intervention. The overall prevalence of thrombophilia calculated from these trials, therefore, may not be truly indicative of the general vascular population who may not even present primary or secondary healthcare.
Thrombophilia and Vascular Risk
Several studies have shown that the Antiphospholipid syndrome is associated with thrombotic events in coronary arterial disease and cerebrovascular disease. 21 -24 Conversely, other studies have reported no significant association between thrombophilia and coronary artery disease (CAD). Gorog et al. reported the coagulation status of 761 patients with CAD awaiting surgery compared to 100 controls. This study reported no difference in the coagulation status of the two groups but showed that platelet reactivity was significantly increased in patients with severe CAD compared to patients with single vessel disease. 25 Ray et al. demonstrated that only a quarter of stable claudicants had evidence of thrombophilia but that the frequency increased to 40% in those patients requiring vascular intervention. 7 Whether patients with PVD and thrombophilia have an increased risk of progression to severe disease is unknown, although this maybe suggested by the higher prevalence of thrombophilia in patients with severe symptomatic disease requiring intervention compared to those with stable claudication. Levy et al. recruited 51 young patients with lower limb atherosclerotic disease, 47 
Thrombophilia and Failure of Intervention
Thrombophilia appeared to be associated with high failure rates of surgical revascularisation procedures and the data are summarised in Table 5 .
Collins et al. reported that patients with markers of hypercoagulability were six times more likely to develop complications than controls (10/13 compared to 2/13). 26 Flinn et al. demonstrated that distal bypasses failed in 33% (5/15) of patients with Antithrombin deficiency compared with 13.4% (9/67) of controls. 12 Donaldson et al.'s prospective study reported that 9% (5/56) of infrainguinal reconstructions developed thrombotic graft occlusions (30 days). These occurred in 50% (3/6) of patients with a thrombophilia defect compared with only 4% (2/50) of the 'normal' group. Graft failure was, therefore, over 12 times more common in patients with a known thrombophilia defect. 13 Elrup-Jorgenson et al. carried out a prospective study of 20 patients below 51 years of age undergoing intervention vascular patients over a 20-month period. Of these, only four had no identifiable thrombophilia defect or platelet problem. Four patients developed thrombotic complications within 30 days. All these four patients had evidence of hypercoagulability. 9 APCR is also associated with early graft occlusion. Ouriel et al. reported that 11.6% of patients had evidence of APCR. Sixty percent (6/10) of patients with APC-R had failed grafts compared to 24% (16/66) in the control group. 16 Patency of infrainguinal reconstruction was 48^12% at 12 months and 33^18% at 5 years in patients with APCR compared to 88^8% at 12 months and 71^13% at 5 years ðp ¼ 0:04Þ in patients with no defect. This study noted that patients who were positive and occluded did so secondary to thrombosis whereas patients who were APCR negative often had a demonstrable anatomical lesion explaining the occlusion.
Ray et al. reported that 20% (12/60) of patients had occluded grafts at 30 days with 11/12 having evidence of thrombophilia defects. This study further demonstrated that the risk of graft failure at 1 year was 65% in those with a hypercoagulable state compared to 17.9% in those with no detectable abnormality. In addition, Lupus anticoagulant was seven times as common in patients who had occluded grafts than in those whose grafts remained patent. Nearly 40% of patients in this study who had undergone a previous revascularisation had evidence of a thrombophilia defect compared to 27% of those with no thrombophilia defect. 27 In contrast, Lee et al.'s study reported that the presence of the antiphospholid antibodies was not detrimental to primary 4-year patency, limb salvage or patient survival. 18 Taylor et al. tested for Antiphospholipid syndrome and questioned patients about previous lower limb surgical revascularisation. This investigation demonstrated that patients with evidence of Antiphospholipid syndrome were twice as likely to have had a previous failed lower limb vascular procedure and six times more likely to have an occlusive cause for failure than those without. 15 Mean graft patency for occluded lower limb procedures was 17 months in patients with APS and 50 months in those without, suggesting that this difference in failure was not just a consequence of duration of follow-up. However, it is known that thrombophilia defects may be acquired after intervention and therefore this may not be a true representation. Nielsen et al. reported the results of 80 patients undergoing infra-inguinal vein bypass surgery. Nine percent of patients had evidence of Anticardiolipin antibodies. Graft thrombosis occurred in 57% of patients with an Anticardiolipin antibody compared to 30% (23/77) of those without. The overall primary patency at 6 months was even lower with 14% in those with Anticardiolipin antibodies compared to 57% in those without ðp ¼ 0:03Þ: 28 Sampram et al. suggested that a factor V Leiden mutation was associated with a doubled rate of failure for infrainguinal procedures both at 1 month and 1 year (37% vs. 22% and 46% vs. 27%) but this was not statistically significant (p ¼ 0:15 and 0.09, respectively). 17 The recent publication by Curi et al. reports that patients with hypercoagulability were more likely to have undergone prior revascularisation than patients deemed 'normal'. 29 The limitation of this retrospective analysis is that only 18% of the group underwent formal thrombophilia screening and so the normal group might contain patients with a thrombophilia defect and there might be an underestimation of the prevalence of 13%. Despite this limitation the 5-year primary patency of infrainguinal reconstructions was poorer in those with defined hypercoagulability (28% vs. 35% p ¼ 0:004). Hypercoagulability also adversely affected secondary patency, limb salvage and survival.
In summary patients with an identifiable thrombophilia defect appear to be more likely to have a failed graft compared to patients tested as 'normal'. The studies suggest that the rate of occlusion maybe 2-12.5 times higher in patients with a thrombophilia defect. Ray's study, which carried out the most comprehensive thrombophilia screen, detected a large significant difference between the occluded and patent groups at 30-day follow-up (11/12 vs. 1/12). 27 The overall wide variation in occlusion rates associated with graft failure is probably due to the variation in thrombophilia defects tested. It is not possible to conclude which thrombophilia defect is most important from the limited data available.
Screening
There is an increased prevalence of thrombotic defects in patients with peripheral arterial disease. The prevalence in young men with PAOD appears to be 15 -30% and is twice that of age matched controls. In the cohort of elderly patients with PAOD the prevalence still appears to be around 30-40%. Thrombophilia appears to increase the risk of thrombotic events not only in the cardiac and cerebral circulation but also following lower limb revascularisation. From the published data available, the risk of graft failure in patients with thrombophilia appears to be three times more likely.
Given that over a quarter of patients presenting with peripheral arterial disease will have thrombophilia and that they are at risk of interventional failure as well as having fatal cardiac and cerebral events, it is difficult to see why patients are not screened for thrombophilia. It has been suggested that a full screen should include a FBC, clotting screen, test for lupus anticoagulant and Activated Protein C resistance in addition to assays of Antithrombin, Protein C and free Protein S. Genetic testing by PCR can screen for Factor V Leiden and the prothrombin gene promoter mutation. These tests are also expensive and may be costed at approximately £250. There are other difficulties as patients presenting with acute disease are often treated with heparin or warfarin, which interferes with many thrombophilia assays. It has also been reported that Antithrombin, Protein C and S deficiency and platelet hyperactivity may manifest de novo in postoperative patients. Ray et al. showed that by the third postoperative day 55% of patients had a thrombophilia abnormality, normally a low Protein C or S. At six-month follow-up these abnormalities returned to Prevalence of Thrombophilia baseline levels. This transient hypercoagulability might be secondary to the ruptured plaque post angioplasty or artificial graft increasing thrombogenic potential and therefore activation of the coagulation system. 30 To date thrombophilia screening has been very cumbersome to perform. However, the advent of automated individual testing of thrombophilia defects has decreased the time for a full thrombophilia test to be reported.
Treatment Options
It is difficult to know how patients with thrombophilic defects should be managed. One option would be to limit the surgical options in patients who are deemed high risk. A patient with critical ischaemia given the knowledge that a graft was likely to fail may opt for an ablative procedure. A claudicant with detected thrombophilia might decide against any surgical intervention.
It has also been difficult to define best possible medical therapy in thrombophilic patients who may require intervention. There are no published trials of medical therapy in patients with thrombophilia and PVD. Treatment of asymptomatic hypercoagulable patients has not been routinely recommended unless there was a strong family history of thrombosis.
Antiplatelet medication
Prophylaxis during surgery or angioplasty may be recommended. It must be remembered that these patients also have generalised atherosclerosis and so there can be no justification in withholding antiplatelet therapy, as antiplatelet agents have been shown to reduce vascular deaths. The Antiplatelet therapy in peripheral arterial disease consensus statement suggests that all patients with intermittent claudication or who have had previous vascular intervention should have long-term antiplatelet medication. 31 In addition, both the systematic overviews of the Antiplatelet Trialists' Collaboration and the Antithrombotic Trialists' Collaboration have provided unequivocal evidence that antiplatelet therapy reduced the odds of arterial or graft occlusion by half and overall serious vascular events by a quarter. 32, 33 Ticlodipine and clopidigrel have been shown to be more effective than aspirin in reducing overall mortality. Both ticlodipine and clopidigrel inhibit the Glycoprotein IIb/IIIa-receptor activation, which is the final common pathway in platelet aggregation and therefore thrombus formation. These drugs could therefore have a substantial role in preventing graft failure due to thrombus. However, there are no robust clinical trials to date in patients undergoing peripheral revascularisation. Ticlodipine requires haematological monitoring as it has a 1% risk of inducing an aplastic anaemia and, therefore, appears less desirable. However, clopidigrel has great potential, as its safety profile appears to be better than ticlodipine and equivalent to medium dose aspirin. The choice between the individual drugs remains an individual decision. Medium dose aspirin remains the most widely tested, most convenient and least expensive antiplatelet treatment.
Anticoagulants
Heparin is used perioperatively to inhibit thrombus formation at the site of revascularisation. It is used widely despite the lack of good published evidence in clinical series. The role of low molecular weight heparin needs to be assessed in the immediate period following revascularisation. It carries a lower risk of bleeding, reducing the need for intensive monitoring of coagulation and decreases the overall costs of treatment.
The role of warfarin is controversial. At present, many surgeons only prescribe warfarin if there is an acute thrombosis, a failed graft requiring revascularisation or a 'gut feeling' that a graft may fail. It is difficult to recommend the use of warfarin routinely in these patients without a large prospectively randomised controlled trial because of the potentially lethal side effects of bleeding. Overall, the annual risk of bleeding on warfarin treatment is approximately 6%, with major and fatal bleeding events estimated to be 2% and 0.8%. 34 The role of the newer Glycoprotein IIb/IIIa platelet receptor inhibitors also needs to be carefully evaluated. These drugs could potentially decrease graft failure secondary to thrombus in hypercoagulable patients. Whether a single infusion at the time of surgery would be enough or whether longer treatment with oral agents would be required needs to be evaluated with a prospective randomised controlled trial.
Conclusion
Optimisation of best medical practice would endeavour to reduce the number of failed grafts. If it is supposed that over 40% of patients undergoing revascularisation exhibit hypercoagulability and that around 60% will occlude their grafts then this would account for 24 patients out of 100. Even if only a third of these patients required re-intervention and possibly amputation the costs are huge.
Any pharmaceutical manipulation that could positively influence the outcome of surgery in patients with thrombophilia surely needs to be evaluated. This can only lead to a reduction in expenditure on redo interventions and an improvement in quality of life.
